The drug regulator for the European Union has stated that its longer approval process for COVID-19 vaccines is safer, Reuters news agency reported on Wednesday.
Emergency authorisation of Pfizer and BioNTech's COID-19 vaccine has been granted by the UK regulator.
Reuters quoted the European Medicines Agency as saying: "EMA considers that the conditional marketing authorisation is the most appropriate regulatory mechanism for use in the current pandemic emergency."
It added that procedure was based on more evidence and more checks than the emergency procedure chosen by the UK.
EMA has said that it will decide on authorisation of Pfizer's vaccine by 29 December 2020.
Applied DNA Advances COVID-19 Diagnostics and Testing Activities
SML Genetree wins FDA's EUA for Ezplex SARS-CoV-2 G PCR Kit with specimen pooling capability
US FDA Clears Vor's IND Application for VOR33
PerkinElmer SARS-CoV-2 RT-PCR Assay Receives FDA EUA for Asymptomatic Testing
Twist Bioscience Begins Shipping of Synthetic RNA Controls for UK Variant Strain of SARS-CoV-2
Philippines FDA approves Pfizer-BioNTech COVID-19 vaccine for emergency use
Johnson & Johnson's COVID-19 vaccine generates immune response in early trials after single dose